RxDoctor Payments Data

Cory Offutt, MD

Family Medicine · Cuba, MONPI 1811330806

Payments from drug & device makers

$1,998in general payments, 2019–2025

Across 121 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$340
  • Pfizer$298
  • Novo Nordisk$234
  • Lilly USA, LLC$216
  • Novartis$129
  • AstraZeneca$115
  • plus $666 from 20 others

What the payments were for

  • Food & beverage$1,98399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,998 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$72,288
Medicare patients
209
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin143$164,471
OzempicSemaglutide76$106,987
TrulicityDulaglutide62$106,415
EliquisApixaban75$87,254
MounjaroTirzepatide29$42,323
RybelsusSemaglutide15$30,014
ArexvyRsvpref3 Antigen/As01e/Pf59$16,351
Spiriva RespimatTiotropium Bromide21$15,890
Tresiba Flextouch U-100Insulin Degludec34$15,781
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$15,515
Breo ElliptaFluticasone/Vilanterol25$10,442
SymbicortBudesonide/Formoterol Fumarate28$6,841
FarxigaDapagliflozin Propanediol11$6,445
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,927
Incruse ElliptaUmeclidinium Bromide13$4,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$13$180,361164 claims
Lilly USA, LLCTrulicity, Mounjaro$216$148,73891 claims
Novo NordiskOzempic, Rybelsus$234$137,00191 claims
PfizerEliquis$298$87,25475 claims
GSKArexvy, Breo Ellipta, Incruse Ellipta$11$30,90897 claims
AstraZenecaSymbicort, Farxiga$115$13,28639 claims
AbbVieSynthroid$340$2,07430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Cuba

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →